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 ABSTRACT: 
 
This paper is the second of three from the Balliol Collaboration on evaluating 
surgical innovation, and considers the methodological and practical challenges to 
rigorous surgical research.   Few, if any, of these challenges apply only to 
surgery.  However, what is arguably unique to surgery is the way in which many 
of these challenges coalesce. We discuss the impact of the challenges 
confronting surgical evaluations in two areas: (1) challenges related to study 
design; and (2) challenges related to the nature of surgical interventions.  The 
first is divided into: challenges of randomised controlled trials for evaluating 
surgical interventions, and challenges of nonrandomised studies for evaluating 
surgical interventions.   The second: complexity and surgical interventions; 
surgeon-related factors; surgical outcome evaluation; and additional challenges 
in surgery.   We conclude that rigorous evaluation, though difficult, is achievable 
and necessary.  It requires surgical “flavoured” solutions and a framework for 
generating evidence on which to base surgical practice.  
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 I. INTRODUCTION 
The Balliol Colloquia considered many challenges facing the surgical research 
community when performing an evaluation of a therapeutic, procedure-based 
intervention.  By identifying many issues and deconstructing them into 
constituent methodological parts, several important areas were targeted for 
developing a systematic process that would guide appropriate, evidence-based 
surgical practice.  This paper is the second of three on evaluating surgical 
innovation, and considers the methodological and practical challenges to 
rigorous surgical researchi.  Few, if any, of these challenges apply only to 
surgery.  Many arise when evaluating other non-pharmacological interventions, 
such as interventional radiology, technical procedures and devices, rehabilitation, 
behavioural interventions, and psychotherapy.1  However, what is arguably 
unique to surgery is the way in which many of these challenges coalesce. 
Perhaps this leads many surgeons to view Randomised Controlled Trials (RCTs), 
while theoretically advantageous, to be too difficult and impractical to conduct, 
and at worst, irrelevant to their practice due to concerns about generalizability.2  
Clearly, most of the same challenges also affect non-randomised studies and in 
some cases to a greater extent.  In spite of the barriers, an RCT remains the 
optimal study design for evaluating therapeutic interventions.  We shall discuss 
the impact of the challenges confronting surgical evaluations in two broad areas:  
(1)  challenges related to study design;  and   
(2) challenges related to the nature of surgical interventions. 
                                                 
i Recommendations for improvement and solutions will be presented in the third paper in this series. 
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 II. CHALLENGES RELATED TO STUDY DESIGN 
 
A. CHALLENGES OF RANDOMISED CONTROLLED TRIALS (RCTs) FOR 
EVALUATING SURGICAL INTERVENTIONS 
Randomised controlled trials (RCTs) are usually considered the gold standard for 
evaluating therapy.  Despite exhortations for surgical research to be more 
rigorous, the overall prevalence of RCTs has been consistently low since the 
1970s.3  Large, high-quality RCTs have been conducted in a variety of surgical 
specialties but those of the surgical procedure itself are less common.  Most 
surgical RCTs have focused on other aspects of the intervention, such as 
anaesthesia or pharmacological interventions, in pre and post-operative care.4  It 
should be noted that there are different types of RCTs which address different 
aims5  A useful distinction can be made between Explanatory trials, which seek 
to assess whether an intervention can work and Pragmatic trials, which seek to 
inform clinical decision-making. The latter are required to ensure surgical practice 
is evidence-based.  Some criticisms of surgical trials are misplaced and reflect 
misunderstanding of the trials’ aims.  Specific challenges to the planning and 
conduct of surgical randomised trials are discussed below and summarised in 
Table 1.  Many of the issues raised may require a different approach depending 
upon the aim of the study. 
 
(i) When Should An RCT Be Conducted? 
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A particularly vexing question in evaluating new surgical interventions is whether 
an RCT is necessary and, if so, when the first one should be conducted.  
Conceptually, there are few arguments against doing RCTs early in 
development, though a further evaluation may be appropriate.  For a new 
surgical intervention, it can be difficult to decide when to shift from an early 
exploratory stage of development to a formal evaluation.  If too early, the 
constraints of an RCT could obstruct innovation, and if too late, equipoise may be 
lost.  Another consequence of an early RCT is that the definitive technique may 
not be fully refined; the subsequent study outcome then reflects the stage of 
development and learning, not the therapeutic impact of the intervention.6  In 
addition, restricting a new procedure to an RCT may be impractical in the 
absence of regulation.7  
 
(ii) Difficulties In Recruitment 
When two interventions have different benefit to harm profiles, patients and 
surgeons may strongly prefer one intervention.  Strong preferences represent a 
lack of equipoise, which may lead both patients and surgeons to decline 
participation and make trial recruitment more difficult if not infeasible.  This is 
particularly problematic when the preferred intervention is already available.  The 
strength of a patient’s preference partly depends on the comparison of interest 
(Table 1).  Possible comparisons are:  a new procedure vs. a “sham” (placebo) 
procedure; similar but distinguishable procedures; dramatically different 
procedures; or surgery vs. a non-surgical treatment such as a medical treatment, 
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participative intervention (e.g. rehabilitation), or “watchful waiting”.  Research to 
evaluate surgical innovations in emergency and pediatric settings are perhaps 
particularly susceptible to preferences which preclude randomisation. 
 
Response to uncertainty has been also suggested as an explanation why 
surgical trials may be more difficult to randomise.  When compared to physicians, 
surgeons may be less tolerant of uncertainty, affecting their participation in 
RCTs.8  Previous negative experiences and perceived threat of litigation may 
make some surgeons reluctant to submit elements of their practice to evaluation.  
A feasibility study of patients’ willingness to participate in surgical and oncology 
trials found a low level of willingness due to a stated dislike for randomisation, 
and a desire to make their own decisions about the selection of the intervention.9  
Preferences, both surgeon and patient, may often not be based on the existing 
evidence.  Patients need to be provided with sufficient information to make 
informed decisions which has not always have been the case.10   Qualitative 
research can provide insights into the recruitment process and may enable 
greater RCT participation.11 
 
(iii) Timing Of The Randomisation Process And Adherence To Allocation 
Randomisation should be as close to the time of the intervention as possible to 
reduce the possibility that the allocated intervention will not be delivered due to 
strong preferences, knowledge of allocation assignment, cancellations, or clinical 
events before the procedure.12 However, it needs to be sufficiently early for the 
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patient and surgical team to be adequately prepared.  In the case of two possible 
surgical procedures, randomisation can often be done in the Operating Room 
(OR).  The challenge is exaggerated when comparing substantially different 
interventions (e.g. surgical vs. pharmacological), where participants have to be 
told their allocation in advance of receiving the intervention, or if the new 
procedure is available outside the trial. Irrespective of the timing of 
randomisation, a surgeon may decide that a surgical procedure is inappropriate, 
impossible, or unsafe after randomization.  The SPORT trial, which compared 
surgery and non-surgical management in low back pain, observed considerable 
crossing over.13  Although the principle of intention-to-treat provides the preferred  
analysis framework for dealing with this, applying the results of such an analysis 
to other settings (e.g., if cross-overs are predominantly from new to conventional 
therapy) can be problematic.  
 
(iv) Lack Of Blinding 
Lack of blinding can lead to several forms of bias:  performance bias (surgeons, 
other caregivers or patients choosing co-interventions conditional on their 
allocation); attrition bias (differential withdrawal of from follow-up); and detection 
bias (differential outcome assessment).14 Blinding of surgeons, patients, and 
other caregivers is difficult and often impossible in surgical trials; nevertheless, 
innovative methods of blinding exist.15 In a comparison of laparoscopic and 
small-incision cholecystectomy, bloody bandages were used to blind patients and 
other caregivers.16 “Sham” (placebo) surgery, whereby the surgeon mimics the 
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intervention, have been used to assess arthroscopy and stem cells for 
Parkinson’s disease.17 18  Their use is controversial, and they have been 
restricted to cases where a suitable comparator was not available or the placebo 
surgery had limited risk.19 Although blinding of the surgeon and patient is difficult, 
it should be possible to blind the clinical assessment of outcomes (though 
seldom done).20 If patients cannot be blinded, some outcomes may be 
susceptible to bias (especially patient reported outcomes).   
 
(v) Alternative RCT Designs 
The principle of randomising participants to surgeons with expertise in carrying 
out different procedures, i.e. an “expertise-based” design (an intrinsic feature of a 
comparison between a surgical procedure and a non-surgical treatment), has 
been proposed for comparing two surgical procedures.21 Like cluster 
randomisation, this design protects against contamination and allows surgeons 
with strong preferences to take part.  However, it brings its own challenges: more 
surgeons are required; the comparison may be confounded by the characteristics 
of surgeons who prefer one technique; and the logistics of shared waiting lists 
across surgeons are formidable. 
 
A “tracker trial” design has been proposed to reflect and incorporate the difficulty 
of incremental and stepwise innovation during evaluation.22 In this design, 
modifications during the conduct of the trial are allowed, recorded, and 
subsequently “tracked” in the statistical analysis.  Variations in the randomisation 
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scheme are also allowed.  In principle, the full development of an innovation can 
be assessed in a single study.  While conceptually attractive, full-fledged tracker 
trials would be extremely challenging in practice. 
 
B. CHALLENGES OF NONRANDOMISED STUDIES (NRS) FOR 
EVALUATING SURGICAL INTERVENTIONS 
As noted above, various factors contribute to make RCTs of surgical procedures 
difficult and, in a few cases, impossible.  For example, lesser surgical variations 
may have such limited influence on outcome so as to make a RCT evaluation 
prohibitively large.  Historically, most advances in surgical knowledge have been 
accepted on the basis of non-randomised studies (NRS).23 Surgical interventions 
such as heart, liver, kidney, and lung transplantation are established therapies in 
developed countries.24  None of these have been validated with RCTs, and it is 
generally considered unethical to do so given the apparent benefit.25 Other 
advances have been identified through observational studies, or even anecdotes, 
because of “dramatic effects”, where bias may be less concerning.26  Exploratory 
initial case reports, or early case series, for new procedures are likely to be 
reported as an NRS.27  Large cohort observational studies have been critically 
and extensively used to develop and validate risk assessment for surgical 
therapies; to monitor safety in practice; to identify treatment effects (adverse or 
beneficial) that may not have been looked for or detected in original studies; and 
to estimate treatment effects when RCTs were deemed infeasible (e.g., rare 
events, observations far in the future).28 Where RCTs are not possible it is 
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essential to conduct high quality nonrandomized studies.29.  A dichotomy 
between randomized and non-randomised studies is somewhat artificial as both 
designs can provide different and complementary evidence.30  For example, a 
non-randomised evaluation of longer term and rare safety outcomes could be 
conducted alongside a RCT. Overall, most surgical studies are non-randomized 
and often retrospective; their quality is also extremely variable and often poor.31 
Prospective comparative designs are substantially more useful case series which 
are over represented.  A significant driving factor behind non-randomized studies 
is that they are easier to perform, increasingly so with electronic data collection 
and standardized databases.32  However, a lack of appropriate planning and 
poor data quality (missing data for important risk factors, inconsistencies, and the 
absence of key diagnostic and operative details) are common problems that tend 
to undermine the validity of non-randomised studies.  
 
Protocol driven studies, which account for all cases and have accurate and 
informative clinical data, are needed.  More attention should be focused on data 
collection to reduce bias due to incomplete data as is the case for RCTs.  
However, even well designed NRS suffer from many of the difficulties faced in 
conducting RCTs.33 For example, the existence of a learning curve (see Section 
IIIB) is a challenge to both randomised and non-randomised evaluations. 
Accounting for any pre-treatment differences between intervention groups is a 
particular concern in non-randomized studies.  Rigorous prospective design, and 
data collection, provide some protection but there is still an underlying reliance 
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on clinical understanding of the condition and its risk factors, along with 
appropriate documentation for any statistical adjustment (such as propensity 
scores) to have validity.34  
 
Finally, causal inferences established in a NRS are considered “weaker” than an 
RCT and needs cautious interpretation.35  Cautionary examples of “established” 
surgical practices validated with NRS and subsequently discontinued after a 
large RCT was conducted abound (e.g. EC-IC bypass36, Carotid Endarterectomy 
widespread use37, lung volume-reduction surgery38). Since current advances 
have been more subtle, the need for RCTs should increase, i.e., the smaller the 
difference in outcome, the greater the need for an RCT. 
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 III. CHALLENGES RELATED TO  
THE NATURE OF SURGICAL INTERVENTIONS 
 
A. COMPLEXITY AND SURGICAL INTERVENTIONS  
We need to recognize that many surgical interventions are complex and require 
appropriate evaluation.39  Surgical interventions, like other non-pharmacological 
interventions such as therapist-based and educational interventions, consist of a 
number of components that cannot be separated.40 This contrasts with most 
pharmacological interventions, which can be readily defined and standardised. 
While the surgical procedure requires attention — a surgical intervention may 
depend on many healthcare professionals and involve other aspects of 
healthcare delivery in ways that a pharmacological intervention does not.  
(Figure 1) 
 
A surgical procedure is primarily delivered by a surgeon, and is influenced by 
characteristics such as surgical skill, decision-making, preferences, and 
experience.  The delivery of a surgical intervention additionally depends on the 
other members of the team (e.g., anaesthetists, nurses, technicians) and pre-
operative and post-operative management (e.g., emergency department, imaging 
services, recovery room, intensive care, and rehabilitation programmes).  This 
complexity often receives limited recognition in the design of surgical evaluations.  
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Indeed, its existence is sometimes used to criticise surgical evaluations for failing 
to control for potential confounding factors.41  
 
A typical complex surgical intervention consists of several interacting 
components.  Consider Coronary Artery Bypass Graft surgery (CABG).   Its aim 
is to revascularize the myocardium by bypassing coronary arteries that are 
stenosed or blocked.  This is achieved by a number of steps that together 
constitute the surgical procedure: opening the chest; harvesting conduits; 
attaching (and later separating) the heart-lung machine; performing the 
anastomoses; reanimating the heart; closing the chest.  In the case of CABG, 
there is limited variation in technique in between surgeons.42 43  However, there 
are many recognized variations in surgical strategy, such as “Off-Pump” CABG 
(“OPCAB”, avoidance of the heart-lung machine), minimally invasive approaches 
(“MIDCAB”), and different choices of bypass conduits (e.g., bilateral mammary 
arteries, radial arteries, etc.). Some decisions are made intra-operatively (e.g., 
whether additional grafts are required) and will depend on the judgment of the 
individual surgeon.  Other co-interventions may be used, such as antifibrinolytic 
agents, insulin, or hypothermia. Pre-operative medical care (e.g., Coronary Care 
Unit-cardiology management, medical management of co-morbidities, blood bank 
management, etc.), roles of other members of the surgical team (e.g. nurses, 
anaesthetists, perfusionists) and post-operative care (e.g. intensive care, acute 
and chronic cardiac rehabilitation) also vary and affect outcomes.44 These 
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supporting components vary between centres, influenced by infrastructure, 
staffing, and local policies.  
 
While an intervention needs to have a coherent aim (or “function”), different 
forms are often available.45  The complexity, and potential variability, of a 
surgical intervention raises two difficult questions for the design of a surgical 
evaluation for which only general answers can be given.  First, when is variation 
in form substantial enough to be worth evaluating?  Secondly, when evaluating 
alternatives, how standardised should they be, given the complexity of the steps 
involved?  Continuing the CABG example, does avoidance of the heart-lung 
machine warrant evaluation (OPCAB)?  If so, how standardised should the 
OPCAB surgical strategy and other steps be?  The impact on health services 
(e.g., equipment resources, staff requirements - such as training); the potential 
for a change in the balance of benefits and harms; or consensus among 
surgeons could justify evaluation of alternatives.  The degree of intervention 
definition and the level of standardisation of the new approach will depend on the 
stage of development and the aim of the evaluation.  The amount of process 
information and monitoring required will depend on how an intervention is defined 
and the degree of standardisation sought.  Very restrictive approaches could limit 
surgeon participation and may not be feasible in some centres. 
 
B. SURGEON-RELATED FACTORS   
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As noted earlier, attributes of the surgeon, such as surgical knowledge, prior 
training and experience, and inherent skills, will influence the delivery of a 
surgical intervention and lead to variability in practice and health outcomes.   
Variability may be expected irrespective of prior training and experience.   
Differences between surgeons interact with patients’ differences affecting the 
responses to operations.  The expectation that all surgeons should attain the 
ideal, often high, level of performance is unrealistic.  Evaluation in a realistic 
setting is important.  
 
The “learning curve” for a surgical intervention, whereby surgeons acquire 
expertise, poses an important challenge.  Since the technical and functional 
success of a procedure is paramount, the early stages of evaluation tend to focus 
on complications, and this where most of the learning curve literature resides.46  
47 For example, the rate of bile duct injuries associated with laparoscopic 
cholecystectomy fell as the surgeon’s experience increased. Proxies for 
operative expertise, such as duration and blood loss, have also been used.48 The 
impact on health outcomes is subject to debate and likely to vary between 
interventions. For complex operations (e.g., radical prostatectomy and 
laparoscopic hernia repair) learning can continue over a very long time, perhaps 
hundreds of procedures.49 50   
 
Evaluation of a new surgical intervention vs. an established control has been 
criticised, owing to a perceived imbalance of experience, favouring the 
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established comparator.51 Some have sought to conduct an evaluation with 
surgeons who have completed their learning.  This strategy is complicated by 
individual surgeons learning at different rates and the effect of external factors on 
the learning process itself.52  Trial design could be modified to incorporate 
individual learning.  Evaluations of surgical innovations should consider the 
influence of learning.  Better recording of surgical training and the experience of 
participating surgeons would be a step forward.  Collection of comprehensive 
data on new interventions, which requires surgeons to document personal 
procedure-based learning, would allow a more informative assessment of 
surgical learning.53  
 
C. SURGICAL OUTCOME EVALUATION  
The key questions with regard to surgical evaluation are: “what” (what is the 
outcome), “how” (how to measure), “who” (who should assess) and “when” 
(when to assess)?  The Quality Assurance literature has used the terms 
“structure”, “process”, and “outcomes” as suggested aspects for evaluation.54 
Traditionally, surgeons themselves have selected and assessed the outcomes, 
mainly focusing on short-term clinical measures of technical success and harm, 
although such outcomes have often not been standardised and reproducible, 
hindering evaluation.  For example, a systematic review revealed 56 separate 
definitions of “anastomotic leak” at any site after gastrointestinal surgery, 
precluding comparability.55  The lack of standardised (agreed upon) surgical 
terminology for the definition of clinical outcomes has long been recognised and 
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this has led to methods of grading and classifying deviations from the normal 
postoperative course have been developed, tested, modified, and validated.56  
One proposed strategy to is to use a validated “therapy-oriented” complication 
classification system, which ranks negative events by severity and avoiding 
confusing terms (TABLE 2).57  It could be adjusted to match a clear and 
consensus definition of specific postoperative events within specific fields of 
surgery.58   
 
Although these surgeon-selected (“physician-centred”) clinical outcomes (e.g. 
mortality and morbidity rates) are critically important to patients, evaluation of 
surgery needs to be widened to include the patient’s perspective.  Patients’ 
perceptions and thus reporting of symptoms and function may differ from the 
surgeon’s assessment and patients may value different outcomes to those of 
interest to surgeons (e.g. social, emotional function). Therefore, surgical 
evaluations require assessment of clinical and patient reported outcomes 
(PROs), i.e., patients, self-reporting without interpretation by an observer. 
Typically this information is captured in questionnaires assessing health-related 
quality of life (HRQL). It can be difficult to decide which are best suited to a 
particular problem. Methodology to select and incorporate assessment of HRQL 
into trials is emerging and better-performed studies will produce more reliable 
data.  Despite the recent interest in this area, however, there appears to be a gap 
between measuring HRQL outcomes and using the information to influence 
surgical practice.59  This may occur because the surgical community does not 
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understand HRQL data, or because clinical outcomes are considered paramount. 
Methods to accurately measure and interpret PROs alongside clinical data are 
needed so that surgeons can effectively evaluate surgery from these different 
perspectives and correspondingly inform patients.  There are also situations 
where PROs matter more than clinical outcomes (e.g. palliative surgery, 
functional outcomes of joint replacement surgery) and capturing this data within 
well-designed trials is critical to optimise outcomes of importance to patients. 
Core outcomes will include key clinical, technical, and patient-reported outcomes 
(generic and/or disease-specific). Additionally, economic evaluation is critical for 
efficient use of often limited resources.  Methods to reach agreement about these 
have been developed in rheumatology.60 
 
What is needed is a more comprehensive approach to evaluating surgery using 
accurate standardized clinical and patient-reported outcomes, recorded in real 
time, and whenever possible by an independent blinded observer.  After the early 
development of surgical interventions, comprehensive evaluation of outcomes is 
recommended for all other stages of development (see table paper 3).  This 
approach provides information to allow evidence-based comparisons among 
different interventions. 
 
D.  ADDITIONAL CHALLENGES IN SURGERY 
(i) Traditional Master-Student Model 
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The traditional hierarchal system of surgery epitomizes “Eminence Based 
Medicine”.  This Master-Student (apprenticeship) tradition holds that the master 
has all the knowledge and skill and the student learns by observation and 
emulation.  It can constrain penetration of new models and information into 
mainstay practice.  Despite attempts to implement change with “knowledge 
translation” methods, dissemination of practice guidelines is poor without the 
assistance of “opinion leaders” in surgery.61   This may help explain, in part, the 
slow acceptance of “Evidence Based Surgery” and RCTs in particular.  Meakins’ 
editorial introducing the first “Users’ Guide for Evidence Based Surgery” did not 
appear until 2001,62 well after the introduction of “Users’ Guides To The Medical 
Literature” in 1993.63  
 
(ii) Lack Of Methodological Expertise  
The basic principles of clinical epidemiology and biostatistics are familiar to 
surgeons, but formal training is rare.  Without a critical mass of methodological 
expertise it has been difficult to transform the surgical culture to an “evidence 
seeking profession”.64 Research funding agencies have developed programmes 
to increase research exposure of junior medical faculty, but there is some 
evidence that surgeons are less likely to apply and are less successful when they 
do.65  Perhaps as important for improved research is increased recognition of the 
need for collaboration between surgeons and methodologists to enable high-
quality and clinically relevant evaluations by combining expertise.  The surgical 
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and research communities as well as funding bodies need to recognize this gap 
in knowledge. 
 
(iii) Academic Careers And Research Support 
Surgeons must devote a significant proportion of their career development to 
their “craft” regardless of a choice for an academic pathway.  Surgical research 
using RCT design methods are not favoured due to their protracted nature and 
when combined with the obligatory time commitments of the operating room, are 
currently not conducive for rapid career advancement.66  In contrast, many 
established (funded) faculty development programmes are in place for basic 
science and medical disciplines when pharmacological interventions are the 
predominant focus.  This has not been the case for surgical researchers, 
although some funding bodies have provided increasing support to improve this, 
a disproportionately smaller number of surgeons are working in this area.67  
 
(iv) Lack Of Regulation 
Surgical research should generally follow the same ethical and scientific 
principles as pharmacological research.  Worldwide mandatory regulations, like 
ICH guidelines, Directives of the European Union and the U.S. FDA, have been 
developed to evaluate drugs.  In surgery, no parallel exist requiring high quality 
evidence prerequisite for full adoption.  Fortunately, this type of evaluation 
through assessment bodies has begun to appear in some developed countries.68 
69  Unlike pharmacological evaluations, industry funding is limited and financing 
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of research by healthcare funders is particularly needed. Whether a regulatory 
framework and an agency for surgical innovation would make a difference to the 
quality of surgical research is speculative. 
 
IV. DISCUSSION 
Rigorous evaluation of surgical innovation, though difficult, is achievable and 
necessary.  There are many challenges, perhaps none of which is unique to 
surgery.  However, they often converge in evaluation of new surgical procedures 
and require surgically “flavoured” solutions.  The complexity of surgical 
interventions makes it difficult, if not generally impossible, to mirror some aspects 
of pharmacological evaluations.  This has contributed to uncertainty about the 
risk of biases and has lead to scepticism about the value of surgical evaluations.  
In some cases, it has become too easy to criticise and ignore if it contradicts 
cherished beliefs or preferences.  While much criticism is aimed at surgical 
RCTs, few of the challenges apply only to RCTs.  It is difficult to predict which 
research questions can be evaluated using a RCT design given appropriate 
funding. The RCT design should be the default choice for a definite evaluation.  
Greater understanding of the processes of evaluation in surgery may lead to 
more high-quality studies.  Surgery does not lack “evaluative” research.  What it 
does lack are accepted guidelines for generating valid evidence: systematic, well 
planned and conducted, and meticulously reported evidence, on which surgical 
practice can be based. 
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TABLE 1:  RCT CHALLENGES BY COMPARATOR 
 
COMPARATOR  
Sham (placebo) 
surgery  
 
Other similar 
surgical 
procedure 
 
Substantially 
different 
surgical 
procedures  
Non surgical 
treatment 
CHALLENGE 
 Stem cells 
for 
Parkinson’s 
(Freeman18
) 
 
 Two versus 
three stage 
postpartum 
perineal repair 
(Gordon 70) 
 
 Open vs. 
minimally 
invasive 
procedures 
(Neumayer50
) 
 Back surgery 
vs. 
physiotherapy 
(Weinstein13) 
 
Randomisation in operating 
room possible 
Yes Yes Likely No, due to 
different providers  
Poor patient participation Yes Unlikely Unlikely 
 
Yes 
Imbalance in surgical expertise No Unlikely Yes No, due to 
different providers 
Poor compliance with allocation 
(i.e. cross over) 
Yes Unlikely 
 
Yes  Yes 
Contamination (i.e. lack of 
fidelity) 
Unlikely Yes Unlikely  Unlikely 
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TABLE 2 
 
 
Grading system proposed in 2004.i The key concept of this scale was that 
objective severity of a complication could be defined by the treatment it provoked 
to reverse it, or death.  
 
 
 
                                                 
i Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a 
cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205–213.  
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FIGURE 1 – COMPLEXITY OF A SURGICAL INTERVENTION  
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